希罗达为基药的同步放化疗用于胃癌根治后疗效观察  

作　　者：崔洪霞[1] 蒋雪超[1] 薛卫红[1] 贾立娟[1] 魏海东[1] 

机构地区：[1]山东省滨州市中心医院,滨州251700

出　　处：《药物与人》2015年第2期19-19,共1页Medicine & People

摘　　要：目的：探讨希罗达为基药的同步放化疗用于胃癌根治后的临床治疗效果。方法：选取来我院进行治疗的胃癌患者148例，按照治疗方式的不同分为对照组和观察组，每组患者74例。对照组患者单纯使用放化疗进行治疗，观察组患者在对照组治疗的基础上加用希罗达药物进行治疗，对患者进行为期一年的随访，观察两组患者的生存率情况，比较两组患者不良反应情况发生的几率。结果：经过治疗后，观察组患者的生存率明显高于对照组患者，P＜0.05，具有显著性差异和统计学意义。在不良反应发生情况方面，对照组患者发生的几率明显高于观察组患者，P＜0.05，具有显著性差异和统计学意义。结论：希罗达应用于放化疗治疗胃癌根治后的临床中效果较为显著，能够降低毒性反应，提高患者的耐受性，具有极强的临床应用价值。Objective：To investigate the Shiroda based medicine synchronous radiotherapy and chemotherapy for gastric cancer after the clinical treatment effect.Methods：gastric cancer treatment cases,in accordance with the different treatments for the control group and the observation group,74 cases in each group of patients. Control group patients were treated with radiotherapy and chemotherapy treatment,the patients in observation group were treated with Xeloda plus drugs based on the treatment in control group,to carry out a one-year follow-up of patient,to observe the survival condition of two groups of patients were compared between the two groups,the probability of adverse reactions occur. Results： after treatment,observe the survival rate was significantly higher than the patients in the control group.Cases occurred in the adverse reaction,the control group was significantly higher than the probability of occurring in patients in the observation group,P〈0.05,with significant differences and statistical significance. Conclusion：the clinical effect of radiotherapy and chemotherapy of Xeloda is applied to the treatment of gastric cancer after the more obvious,can reduce the toxicity,enhance the tolerance of patients,with strong clinical value.

关 键 词：希罗达 同步放化疗 胃癌根治 

分 类 号：R735.1[医药卫生—肿瘤]